• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE DIAGNOSTICS ELECSYS FT4 III ASSAY; RADIOIMMUNOASSAY, FREE THYROXINE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE DIAGNOSTICS ELECSYS FT4 III ASSAY; RADIOIMMUNOASSAY, FREE THYROXINE Back to Search Results
Model Number FT4 G3
Device Problem Incorrect, Inadequate or Imprecise Result or Readings (1535)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 12/12/2020
Event Type  malfunction  
Manufacturer Narrative
This event occurred in (b)(4).
 
Event Description
The initial reporter stated they received discrepant results for one patient sample tested with the following assays on two cobas 8000 e 602 module analyzers: the elecsys tsh assay, the elecsys tsh assay ver.2, elecsys ft3 iii, the elecsys ft4 iii assay, the elecsys anti tshr immunoassay, and the elecsys anti-tshr ver.2 immunoassay.This medwatch will cover the ft4 assay.Refer to the medwatches with the following a1.Pt (b)(6) for tsh.Refer to the attachment for all patient sample data.The sample was collected on (b)(6) 2020 and run five times on the customer's e 602 analyzer on (b)(6) 2020.The sample was also diluted x2 and repeated for tsh and tsh v2 on the customer's e 602 analyzer.The sample was repeated on an abbott architect analyzer.The sample was also provided for investigation, where it was tested on a second e 602 analyzer on (b)(6) 2020.The serial number of the customer's e 602 analyzer is 15d5-11.The ft4 reagent lot number and expiration date used on this analyzer is unknown.The serial number of the e 602 analyzer used for investigation is 1286-07.Ft4 reagent lot number 478085, with an expiration date of may 2021 was used on this analyzer.
 
Manufacturer Narrative
Investigations of the sample were able to reproduce the results obtained by the customer.The sample did not contain an interfering factor against the streptavidin component of the assay.Further measurements of the sample determined that it contains a biotin concentration of approximately 500 ng/ml.The high concentration of biotin can explain the discrepant values generated with the tsh, anti-tshr, ft3, and ft4 assays as the concentration exceeds the maximum threshold for biotin allowed for these assays.Tsh v2 and anti-tshr v2 have a higher biotin tolerance and are not affected.The results generated with these assays can be expected to be correct.Product labeling for ft4 indicates: the assay is unaffected by biotin at concentrations <= 100 ng/ml."samples should not be taken from patients receiving therapy with high biotin doses (i.E.> 5 mg/day) until at least 8 hours following the last biotin administration".Medwatch fields d1., d2., d4., and g5.Have been updated.Medwatch field d4.Udi number = (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ELECSYS FT4 III ASSAY
Type of Device
RADIOIMMUNOASSAY, FREE THYROXINE
Manufacturer (Section D)
ROCHE DIAGNOSTICS
9115 hague road
indianapolis IN 46250 0457
MDR Report Key11125615
MDR Text Key256451433
Report Number1823260-2021-00051
Device Sequence Number1
Product Code CEC
Combination Product (y/n)N
PMA/PMN Number
K131244
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,u
Type of Report Initial,Followup
Report Date 03/31/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberFT4 G3
Device Catalogue Number07976836190
Device Lot NumberASKU, 478085
Was Device Available for Evaluation? Yes
Initial Date Manufacturer Received 12/12/2020
Initial Date FDA Received01/06/2021
Supplement Dates Manufacturer Received12/12/2020
Supplement Dates FDA Received03/31/2021
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Age50 YR
-
-